Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of zoliflodacin versus ceftriaxone + azithromycin for uncomplicated urogenital gonorrhoea
NL-OMON54942Phase 3Completed
- Sponsor
- GARDP
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoliflodacin in gonorrhea (2 arms), sponsored by GARDP. Primary endpoint: Microbiological cure at urogenital site. Started Jun 2020; status: completed.
02
Drugs
zoliflodacin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NL-OMON54942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54942.